Amarin Pharma sued Hikma Pharmaceuticals, claiming Hikma's public statements encouraged doctors to infringe Amarin's patent on its drug Vascepa. A district court threw out the complaint. The Supreme Court must decide whether those statements can count as actively inducing patent infringement.
Case
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
The government ended temporary protected status for Syria and Haiti. The Supreme Court must decide whether a law barring court review of that decision also blocks judges from checking required steps, like consulting other agencies, before the decision was made.